Skip to main content
Illustration of the intricate organization of the PKA structure, wherein different parts of the protein are connected through elaborate hydrogen bonding networks (dashed yellow lines), glued together by the hydrophobic assemblies (light blue and orange volumes)—all working together to build the functional active site. Insert shows protonation of the transferred phosphoryl group (cyan mesh) and its many interactions with water and the active site amino acid residues. Credit: Jill Hemman/ORNL

OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.

(From left) ORNL Associate Laboratory Director for Computing and Computational Sciences Jeff Nichols; ORNL Health Data Sciences Institute Director Gina Tourassi; DOE Deputy Under Secretary for Science Thomas Cubbage; ORNL Task Lead for Biostatistics Blair Christian; and ORNL Research Scientist Ioana Danciu were invited to the White House to showcase an ORNL-developed digital tool aimed at better matching cancer patients with clinical trials.

OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.

carbon nanospikes

OAK RIDGE, Tenn., March 1, 2019—ReactWell, LLC, has licensed a novel waste-to-fuel technology from the Department of Energy’s Oak Ridge National Laboratory to improve energy conversion methods for cleaner, more efficient oil and gas, chemical and

ORNL alanine_graphic.jpg

OAK RIDGE, Tenn., Jan. 31, 2019—A new electron microscopy technique that detects the subtle changes in the weight of proteins at the nanoscale—while keeping the sample intact—could open a new pathway for deeper, more comprehensive studies of the basic building blocks of life. 

mirrorAsymmetry-NPDGamma_ORNL.jpg

A team of scientists has for the first time measured the elusive weak interaction between protons and neutrons in the nucleus of an atom. They had chosen the simplest nucleus consisting of one neutron and one proton for the study.

OAK RIDGE, Tenn., Nov. 27, 2018—The Spallation Neutron Source at the Department of Energy’s Oak Ridge National Laboratory has broken a new record by ending its first neutron production cycle in fiscal year 2019 at its design power level of 1.4 megawatts.

The Spallation Neutron Source at the Department of Energy’s Oak Ridge National Laboratory has broken a new record by ending its first neutron production cycle in fiscal year 2019 at its design power level of 1.4 megawatts.

Two neutron diffraction experiments (represented by pink and blue neutron beams) probed a salty solution to reveal its atomic structure. The only difference between the experiments was the identity of the oxygen isotope (O*) that labeled nitrate molecules

Scientists at the Department of Energy’s Oak Ridge National Laboratory used neutrons, isotopes and simulations to “see” the atomic structure of a saturated solution and found evidence supporting one of two competing hypotheses about how ions come

Infected Poplar

Scientists studying a valuable, but vulnerable, species of poplar have identified the genetic mechanism responsible for the species’ inability to resist a pervasive and deadly disease. Their finding, published in the Proceedings of the National Academy of Sciences, could lead to more successful hybrid poplar varieties for increased biofuels and forestry production and protect native trees against infection.

Radiochemical technicians David Denton and Karen Murphy use hot cell manipulators at Oak Ridge National Laboratory during the production of actinium-227.

The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.